Perspective Therapeutics Inc (CATX)

[Seventeenseconds]

Analyst Jason Kolbert noted, “Isoray has received more physician and medical center inquires about Cs-131 in April 2015 alone than in the previous 2 years. We believe this bodes very well for the forward outlook to gain traction for Cs-131 adoption. Physician adoption is key to Cs-131 and Isoray's success. Isoray, through multiple publications, and abstract presentations at major conferences, is driving awareness to plant the seeds (no pun intended) for Cs-131 adoption.”

Overall: “We believe Cs-131 is a more efficacious, safer alternative to SOC isotopes Iodine-125 or Palladium-103. Cs-131 hits the tumor faster and harder (shorter half life) which should convince physicians to adopt. As Cs-131 is now in centers in the east, west and central parts of the US, we believe adoption will continue. More data and more publications are coming to help the push.”